SGMO
Sangamo Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.54 / 10
Netural
Fund flow analysis reveals a good score of 7.79/10, with overall and block inflows positive, though medium, large, and extra-large flows are mixed. Analyst coverage is limited to one neutral rating from Barclays, providing no strong directional cue. The combination of robust fund inflows and neutral analyst stance suggests potential accumulation by institutions despite weak technicals.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-07
InstitutionBarclays
Times predicted2
Historical Win Rate100.0%
Is money flowing into or out of SGMO?
- SGMO holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.54/10 (Netural).
